Human uterine smooth muscle and leiomyoma cells differ in their rapid 17/J-estradiol signaling: Implications for proliferation

Endocrinology

Volumn 150, Issue 5, 2009, Pages 2436-2445

  Nierth Simpson, Erica N ^a   Martin, Melvenia M ^a,b   Chiang, Tung Chin ^a   Melnik, Lilia I ^a   Rhodes, Lyndsay V ^a   Muir, Shannon E ^a   Burow, Matthew E ^a   McLachlan, John A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; ESTRADIOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; LEIOMYOMA; MOUSE; MYOMETRIUM; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TUMOR CELL; WESTERN BLOTTING; ANIMAL; CELL LINE; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TIME; TUMOR CELL CULTURE; UTERUS; UTERUS CANCER; XENOGRAFT;

ANIMALS; CELL LINE; CELL PROLIFERATION; ESTRADIOL; FEMALE; HUMANS; LEIOMYOMA; MICE; MICE, NUDE; MYOCYTES, SMOOTH MUSCLE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS; UTERUS;

EID: 66449116742     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0224     Document Type: Article

References (96)

1. Flake GP, Andersen J, Dixon D 2003 Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 111:1037-1054 (Review)
2. Newbold RR, Di Augustine RP, Risinger JI, Everitt JI, Walmer DK, Parrott EC, Dixon D 2000 Advances in uterine leiomyoma research: conference overview, summary, and future research recommendations. Environ Health Perspect 108(Suppl 5):769-773 (Review)
3. Lumsden MA, Wallace EM 1998 Clinical presentation of uterine fibroids. Baillieres Clin Obstet Gynaecol 12:177-195
4. Al-Hendy A, Salama SA 2006 Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril 86:686-693
5. Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT 1986 Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J Clin Res Ed [Erratum (1986) 293:1027] 293:359-362
6. Marshall LM, Spiegelman D, Goldman MB, Manson JE, Colditz GA, Barbieri RL, Stampfer MJ, Hunter DJ1998 A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Ferti Steril 70:432-439
7. Cook JD, Davis BJ, Cai SL, Barrett JC, Conti CJ, Walker CL 2005 Interaction between genetic susceptibility and early-life environmental exposure determines tumor-suppressor-gene penetrance. ProcNatl Acad Sci USA 102:8644-8649
8. Newbold RR, Moore AB, Dixon D 2002 Characterization of uterine leiomyo- mas in CD-1 mice following developmental exposure to diethylstilbestrol (DES). Toxicol Pathol 30:611-616
9. Baird DD, Newbold R 2005 Prenatal diethylstilbestrol (DES) exposure is associated with uterine leiomyoma development. Reprod Toxicol 20:81-84
10. McLachlan JA, Newbold RR, Bullock BC 1980 Long-term effects on the female mouse genital tract associated with prenatal exposure to diethylstilbestrol. Cancer Res 40:3988-3999
11. Marshall LM, Spiegelman D, Manson JE, Goldman MB, Barbieri RL, Stampfer MJ, Willett WC, Hunter DJ 1998 Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. Epidemiology 9:511-517
12. Pedeutour F, Ligon AH, Morton CC 1999 [Genetics of uterine leiomyomata] (French). Bull Cancer 86:920-928 (Review)
13. Ligon AH, Morton CC 2001 Leiomyomata: herit ability and cytogeneticstud- ies. Hum Reprod Update 7:8-14 (Review)
14. Sornberger KS, Weremowicz S, Williams AJ, Quade BJ, LigonAH, Pedeutour F, Vanni R, Morton CC 1999 Expression of HMGIY in three uterine leiomyomata with complex rearrangements of chromosome 6. Cancer Genet Cytogenet 114:9-16
15. Rein MS, Powell WL, Walters FC, Weremowicz S, Cantor RM, Barbieri RL, Morton CC 1998 Cytogenetic abnormalities in uterine myomas are associated with myoma size. Mol Hum Reprod 4:83-86
16. Sampath D, Zhu Y, Winneker RC, Zhang Z 2001 Aberrant expression of Cyr61, a member of the CCN (CTGF/Cyr61/Cef10/NOVH) family, and dys- regulation by 17/3-estradiol and basic fibroblast growth factor in human uterine leiomyomas. JClin Endocrinol Metab 86:1707-1715
17. Li S, Chiang TC, Davis GR, Williams RM, Wilson VP, McLachlan JA 2001 Decreased expression of Wnt7a mRNA is inversely associated with the expression of estrogen receptor-a in human uterine leiomyoma. J Clin Endocrinol Metab 86:454-457
18. Li S, Chiang TC, Richard-Davis G, Barrett JC, Mclachlan JA 2003 DNA hypomethylation and imbalanced expression of DNA methyltransferases (DNMT1, 3A, and 3B) in human uterine leiomyoma. Gynecol Oncol 90:123-130
19. Li S, McLachlan JA2001 Estrogen-associated genesinuterineleiomyoma. Ann NY Acad Sci 948:112-120
20. Kawaguchi K, Fujii S, Konishi I, Iwai T, Nanbu Y, Nonogaki H, Ishikawa Y, Mori T 1991 Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Arch A Pathol Anat Histopathol 419: 309-315
21. Dixon D, Flake GP, Moore AB, He H, Haseman JK, Risinger JI, Lancaster JM, Berchuck A, Barrett JC, Robboy SJ 2002 Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch 441:53-62
22. Maruo T, Ohara N, Wang J, Matsuo H 2004 Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 10:207-220 (Review)
23. Cook JD, Walker CL 2004 Treatment strategies for uterine leiomyoma: the role of hormonal modulation. Semin Reprod Med 22:105-111 (Review)
24. Walker CL2002 Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. Rec Prog Horm Res 57:277-294
25. Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD1991 Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol 77:720-725
26. Walker CL, Burroughs KD, Davis B,Sowell K, Everitt JI, Fuchs-Young R2000 Pre clinical evidence for the rapeutic efficacy of selective estrogen receptormod- ulators for uterine leiomyoma. J Soc Gynecol Investig 7:249 -256
27. Fuchs-Young R, Howe S, Hale L, Miles R, Walker C 1996 Inhibition of estrogen-stimulatedgrowthofuterineleiomyomasbyselectiveestrogenreceptor modulators. Mol Carcinogen 17:151-159
28. Al-Hendy A, Lee EJ, Wang HQ, Copland JA 2004 Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptorinhibitstumorgrowthinnudemice. Am J Obstet Gynecol 191:1621-1631
29. Al-Hendy A, Salama S 2006 Gene therapy and uterine leiomyoma: a review. Hum Reprod Update 12:385-400 (Review)
30. Maruo T, Matsuo H, Shimomura Y, Kurachi O, Gao Z, Nakago S, Yamada T, ChenW, WangJ2003 Effectsofprogesteroneon growthfactor expression in human uterine leiomyoma. Steroids 68:817-824
31. Yamada T, Nakago S, Kurachi O, Wang J, Takekida S, Matsuo H, Maruo T 2004 Progesterone down-regulates insulin-like growth factor-I expression in cultured human uterine leiomyoma cells. Hum Reprod 19:815-821
32. Walker CL, Cesen-Cummings K, Houle C, Baird D, Barrett JC, Davis B2001 Protective effect of pregnancy for development of uterine leiomyoma. Carcinogenesis 22:2049-2052
33. Shynlova O, Oldenhof A, Dorogin A, Xu Q, Mu J, Nashman N, Lye SJ 2006 Myometrial apoptosis: activation of the caspase cascade in the pregnant rat myometrium at midgestation. Biol Reprod 74:839-849
34. Levin ER 2001 Cell localization, physiology, and nongenomic actions of estrogen receptors. J Appl Physiol 91:1860 -1867 (Review)
35. Cato AC, Nestl A, Mink S 2002 Rapid actions of steroid receptors in cellular signaling pathways. Sci STKE:RE9
36. Coleman KM, Smith CL 2001 Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. Front Biosci 6:D1379-D1391
37. Driggers PH, Segars JH 2002 Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab 13:422-427
38. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M2000 Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacol Rev 52:513-556
39. Levin ER 2005 Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 19:1951-1959 (Review)
40. Kelly MJ, Levin ER 2001 Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 12:152-156 (Review)
41. Cho H, Katzenellenbogen BS 1993 Synergistic activation of estrogen receptor- mediated transcription by estradiol and protein kinase activators. Mol Endocrinol 7:441-452
42. Pedram A, Razandi M, Aitkenhead M, Hughes CC, Levin ER 2002 Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J Biol Chem 277:50768-50775
43. Vasudevan N, Kow LM, Pfaff DW 2001 Early membrane estrogenic effects required for full expression of slower genomic actions in a nerve cell line. Proc Natl Acad Sci USA 98:12267-12271
44. Acconcia F, Marino M 2003 Synergism between genomic and non genomic estrogen action mechanisms. IUBMB Life 55:145-150
45. Ahn WS, Kim KW, Bae SM, Yoon JH, Lee JM, NamkoongSE, Kim JH, Kim CK, Lee YJ, Kim YW 2003 Targeted cellular process profiling approach for uterine leiomyoma using cDNA microarray, proteomics and gene ontology analysis. Int JExp Pathol 84:267-279
46. Catherino WH, Leppert PC, Stenmark MH, Payson M, Potlog-Nahari C, Nieman LK, Segars JH 2004 Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chromosomes Cancer 40:204-217
47. Hoffman PJ, Milliken DB, Gregg LC, Davis RR, Gregg JP 2004 Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis. Fertil Steril 82:639-649
48. Quade BJ, Wang TY, Sornberger K, Dal Cin P, Mutter GL, Morton CC 2004 Molecularpathogenesis ofuterinesmoothmuscletumorsfromtranscriptional profiling. Genes Chromosomes Cancer 40:97-108
49. Skubitz KM, Skubitz AP 2003 Differential gene expression in uterine leiomyoma. J Lab Clin Med 141:297-308
50. Swartz CD, Afshari CA, Yu L, Hall KE, Dixon D 2005 Estrogen-induced changesinIGF-I, Myb familyandMAPkinasepathwaygenesinhumanuterine leiomyoma and normal uterine smooth muscle cell lines. Mol Hum Reprod 11:441-450
51. Tsibris JC, Segars J, Coppola D, Mane S, Wilbanks GD, O'Brien WF, Spellacy WN 2002 Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril 78:114-121
52. Wang H, Mahadevappa M, Yamamoto K, Wen Y, Chen B, Warrington JA, Polan ML 2003 Distinctive proliferative phase differences in gene expression in human myometrium and leiomyomata. Fertil Steril 80:266-276
53. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R 2008 Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68:826-833
54. Tommola P, Pekonen F, Rutanen EM 1989 Binding of epid ermal growth factor and insulin-like growth factor I in human myometrium and leiomyomata. Obstet Gynecol 74:658-662
55. Chandrasekhar Y, Heiner J, Osuamkpe C, Nagamani M 1992 Insulin-like growth factor I and II binding in human myometrium and leiomyomas. Am J Obstet Gynecol 166(1 Pt 1):64-69
56. Van der Ven LT, Roholl PJ, Gloudemans T, Van Buul-Offers SC, Welters MJ, Bladergroen BA, Faber JA, Sussenbach JS, Den Otter W 1997 Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues. Br JCancer 75:1631-1640
57. Burroughs KD, Howe SR, Okubo Y, Fuchs-YoungR, LeRoithD, WalkerCL 2002 Dysregulation of IGF-I signaling in uterine leiomyoma. J Endocrinol 172:83-93
58. Acconcia F, Totta P, Ogawa S, Cardillo I, Inoue S, Leone S, Trentalance A, Muramatsu M, Marino M 2005 Survival versus apoptotic 17/3-estradiol effect: role of ERa and ER/3 activated non-genomic signaling. J Cell Physiol 203:193-201
59. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C 2000 EstrogenreceptorarapidlyactivatestheIGF-1 receptorpathway. JBiol Chem 275:18447-18453
60. Surmacz E, Bartucci M 2004 Role of estrogen receptor a in modulating IGF-I receptor signaling and function in breast cancer. J Exp Clin Cancer Res 23:385-394
61. Andersen J, DyReyes VM, Barbieri RL, Coachman DM, Miksicek RJ 1995 Leiomyoma primary cultures have elevated transcriptional response to estrogen compared with autologous myometrial cultures. J Soc Gynecol Investig 2:542-551
62. Burroughs KD, Fuchs-Young R, Davis B, Walker CL 2000 Altered hormonal responsiveness of proliferation and apoptosis during myometrial maturation and the development of uterine leiomyomas in the rat. Biol Reprod 63:1322-1330
63. Cook SJ, McCormick F1993 Inhibition by cAMP of Ras-dependent activation of Raf. Science 262:1069-1072
64. Gerits N, Kostenko S, Shiryaev A, Johannessen M, Moens U 2008 Relations between the mitogen-activated protein kinase and the cAMP-dependent protein kinase pathways: comradeship and hostility. Cell Signal 20:1592-1607
65. Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ, Sturgill TW1993 Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3' ,5 '-mono- phosphate. Science 262:1065-1069
66. Bit RA, Davis PD, Elliott LH, Harris W, Hill CH, Keech E, Kumar H, Lawton G, Maw A, Nixon JS, et al 1993 Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction. J Med Chem 36:21-29
67. Twomey B, Muid RE, Nixon JS, Sedgwick AD, Wilkinson SE, Dale MM1990 The effect of new potent selective inhibitors of protein kinase C on the neu- trophil respiratory burst. Biochem Biophys Res Commun 171:1087-1092
68. Severino MF, Murray MJ, Brandon DD, Clinton GM, Burry KA, Novy MJ 1996 Rapidlossofoestrogenandprogesteronereceptorsinhumanleiomyoma and myometrial explant cultures. Mol Hum Reprod 2:823-828
69. Carney SA, Tahara H, Swartz CD, RisingerJI, He H, Moore AB, HasemanJK, Barrett JC, Dixon D 2002 Immortalization of human uterine leiomyoma and myometrial cell lines after induction of telomerase activity: molecular and phenotypic characteristics. Lab Invest 82:719 -728
70. Benassayag C, Leroy MJ, Rigourd V, Robert B, Honore JC, Mignot TM, Vacher-Lavenu MC, Chapron C, Ferre F 1999 Estrogen receptors (ERa/ER/3) innormal and pathological growth of the human myometrium: pregnancyand leiomyoma. Am J Physiol 276(6 Pt 1):E1112-E1118
71. Evinger 3rd AJ, Levin ER 2005 Requirements for estrogen receptor a membrane localization and function. Steroids 70:361-363 (Review)
72. McLachlan JA, Nelson KG, Takahashi T, Bossert NL, Newbold RR, Korach KS 1991 Do growth factors mediate estrogen action in the uterus? In: Hoch- berg RB, Naftolin F, eds. The new biology of steroid hormones. New York: Raven Press; 337-344
73. Ignar-Trowbridge DM, Pimentel M, Teng CT, Korach KS, McLachlan JA 1995 Cross-talk between peptide growth factor and estrogen receptor signaling systems. Proceedings of the Conference on Estrogens in the Environment III: Global Health Implications. Environ Health Perspect 103(Suppl 7):35-38
74. Gao Z, Matsuo H, Wang Y, Nakago S, Maruo T 2001 Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 86:5593-5599
75. Szego CM, Davis JS1967 Adenosine3',5'-mono phosphate in ratuterus: acute elevation by estrogen. Proc Natl Acad Sci USA 58:1711-1718
76. Price SA, Bernal AL 2001 Uterine quiescence: the role of cyclic AMP. Exp Physiol 86:265-272 (Review)
77. Acconcia F, Kumar R 2006 Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett 238:1-14 (Review)
78. Boyan BD, Sylvia VL, Frambach T, Lohmann CH, Dietl J, Dean DD, Schwartz Z 2003 Estrogen-dependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative HCC38 cells is membrane-mediated and inhibited by tamoxifen. Endocrinology 144:1812-1824
79. Sylvia VL, Hughes T, Dean DD, Boyan BD, Schwartz Z 1998 17/3-Estradiol regulation of protein kinase C activity in chondrocytes is sex-dependent and involves nongenomic mechanisms. J Cell Physiol 176:435-444
80. Marino M, Distefano E, Caporali S, Ceracchi G, Pallottini V, Trentalance A 2001 -Estradiol stimulation of DNA synthesis requires different PKC iso-forms in HepG2 and MCF7 cells. J Cell Physiol 188:170-177
81. Tertrin-Clary C, Eude I, Fournier T, Paris B, Breuiller-Fouche M, Ferre F1999 Contribution of protein kinase C to ET-1-induced proliferation in human myometrial cells. Am J Physiol 276:E503-E511
82. Eude I, Tertrin-Clary C, Vacher-Lavenu MC, Chapron C, Ferre F, Breuiller- FoucheM 2001 Differential regulation of protein kinase C isoforms in human uterine leiomyoma. Gynecol Obstet Invest 51:191-196
83. Seki T, Matsubayashi H, Amano T, Shirai Y, Saito N, Sakai N 2005 Phosphorylation of PKC activation loop plays an important role in receptor-mediated translocation of PKC. Genes Cells 10:225-239
84. Pears C, Stabel S, Cazaubon S, Parker PJ1992 Studies on the phosphorylation of protein kinase Ca. Biochem J283(Pt 2):515-518
85. Migliaccio S, Washburn TF, Fillo S, Rivera H, Teti A, Korach KS, Wetsel WC 1998 Modulationofestrogenreceptorlevelsinmouseuterusbyproteinkinase C isoenzymes. Endocrinology 139:4598-4606
86. Ruzycky AL, Kulick A 1996 Estrogen increases the expression of uterine protein kinase C isozymes in a tissue specific manner. Eur JPharmacol 313:257-263
87. Dubey RK, Gillespie DG, Mi Z, Rosselli M, Keller PJ, Jackson EK 2000 Estradiol inhibits smooth muscle cell growth in part by activating the cAMP- adenosine pathway. Hypertension 35(1 Pt 2):262-266
88. Morey AK, Pedram A, Razandi M, Prins BA, Hu RM, Biesiada E, Levin ER 1997 Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology 138:3330-3339
89. Harrington WR, Kim SH, Funk CC, Madak-Erdogan Z, Schiff R, Katzenellenbogen JA, Katzenellenbogen BS 2006 Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocrinol 20:491-502
90. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F 1996 Tyrosine kinase/p21ris/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15:1292-1300
91. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D, Rapp UR 1993 Protein kinase Ca activates RAF-1 by direct phosphorylation. Nature 364:249-252
92. Kisielewska J, Flint AP, Ziecik AJ1996 Phospholipase Candadenylatecyclase signalling systems in the action of hCG on porcine myometrial smooth muscle cells. JEndocrinol 148:175-180
93. Eude I, Dallot E, Ferre F, Breuiller-FoucheM 2002 Protein kinase Ca is required for endothelin-1-induced proliferation of human myometrial cells. Biol Reprod 66:44-49
94. Keyes LE, Moore LG, Walchak SJ, Dempsey EC 1996 Pregnancy-stimulated growth of vascular smooth muscle cells: importance of protein kinase C-de- pendent synergy between estrogen and platelet-derived growth factor. J Cell Physiol 166:22-32
95. Cesen-Cummings K, Walker CL, Davis BJ 2000 Lessons from pregnancy and parturition: uterine leiomyomas result from discordant differentiation and dedifferentiation responses in smooth muscle cells. Med Hypotheses 55:485-490
96. Cesen-Cummings K, Houston KD, Copland JA, Moorman VJ, Walker CL, Davis BJ 2003 Uterine leiomyomas express myometrial contractile-associated proteins involved in pregnancy-related hormone signaling. J Soc Gynecol Investig 10:11-20